BIO-RAD LABORATORIES executive Evran Sedat exercised Options for 1,891 shares at $0 per share across two transactions, leaving 1,728 derivative securities. For investors, the report separates common-share ownership from derivative-security holdings, while a separate award left 4,026 derivative securities in Sedat’s reported holdings.
Key Highlights
- Evran Sedat received an award of 4,026 derivative securities on September 4.
- The award represented about 100.0% of Sedat’s resulting derivative-securities holding.
- Transactions coded F were completed at $386.11 per share, after which Sedat owned 3,603 shares.
BIO-RAD LABORATORIES, INC. (NYSE: BIO) executive Evran Sedat exercised options for 1,891 shares at $0 per share across two transactions between September 5 and September 6. Sedat serves as executive vice president of Global Supply Chain. The transactions left Sedat with 3,880 shares.
Share Transactions and Updated Ownership
The option exercises carried SEC transaction code M. Separate transactions coded F were completed at $386.11 per share, after which Sedat owned 3,603 shares. The reported activity occurred between September 5 and September 6.
Derivative Securities Held After Exercise
Sedat received 4,026 derivative securities on September 4 through a transaction coded A. That award represented about 100.0% of the resulting derivative-securities holding. Sedat then exercised options for 1,891 derivative securities at $0 per share across two transactions. Following those transactions, Sedat owned 1,728 derivative securities. Transaction code M denotes the exercise or conversion of a derivative security.
FAQs
Q: How many Bio-Rad options did Evran Sedat exercise?
A: Evran Sedat exercised options for 1,891 BIO-RAD LABORATORIES shares across two transactions, as stated in the filing. The exercise price was $0 per share.
Q: What happened to Evran Sedat’s Bio-Rad share holdings?
A: Sedat owned 3,880 shares after the option transactions. Following separate transactions coded F at $386.11 per share, reported ownership was 3,603 shares.
Q: How many derivative securities did Sedat hold after the transactions?
A: Sedat owned 1,728 derivative securities after exercising 1,891 options. A separate award had produced 4,026 derivative securities on September 4.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.